COMMUNIQUÉS West-GlobeNewswire

Nation’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search
21/01/2026
The Regeneron Science Talent Search Honors America’s Brightest Young Scientists Advancing Discovery and Innovation TARRYTOWN N.Y. and WASHINGTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Society for Science (the Society) and [...]
IBA SA – NOTIFICATION TRANSPARENCE
21/01/2026
(article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes) Louvain-la-Neuve, Belgique, le 21 janvier 2026, 18:00 Résumé de la notification IBA (Ion Beam Applications SA), le [...]
IBA – TRANSPARENCY NOTIFICATION
21/01/2026
(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, January 21, 2026 06:00 PM Summary of the notification IBA (Ion Beam Applications), the world leader in [...]
OSE Immunotherapeutics salue l'octroi de la désignation de médicament orphelin par la FDA du pegrizprument (VEL-101)
21/01/2026
OSE Immunotherapeutics salue l'octroi de la désignation de médicament orphelin par la FDA du pegrizprument (VEL-101) Nantes, le 21 janvier, 18 heures - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo : OSE) prend [...]
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101)
21/01/2026
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) Nantes, France, January 21, 2026 – 6pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today acknowledges [...]
AB Science obtient un brevet japonais pour l'utilisation du masitinib dans le traitement des formes progressives de la sclérose en plaques (SEP) jusqu'en 2041
21/01/2026
COMMUNIQUÉ DE PRESSE AB SCIENCE OBTIENT UN BREVET JAPONAIS POUR L'UTILISATION DU MASITINIB DANS LE TRAITEMENT DES FORMES PROGRESSIVES DE LA SCLÉROSE EN PLAQUES (SEP) JUSQU'EN 2041 IL S'AGIT DU PREMIER PAYS À OCTROYER LE [...]
AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041
21/01/2026
PRESS RELEASE AB SCIENCE RECEIVES JAPANESE PATENT PROTECTION FOR THE USE OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) UNTIL 2041 THIS IS THE FIRST COUNTRY DELIVERING THE MS PATENT MASITINIB HAS UNIQUE [...]
Nation’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search
21/01/2026
The Regeneron Science Talent Search Honors America’s Brightest Young Scientists Advancing Discovery and Innovation TARRYTOWN, N.Y. and WASHINGTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Society for Science (the Society) and [...]
Smith+Nephew completes acquisition of Integrity Orthopaedics; establishes unrivalled portfolio for shoulder repair
21/01/2026
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has completed the acquisition of Integrity Orthopaedics, further strengthening its sports medicine shoulder repair business with [...]
Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026
21/01/2026
MELBOURNE, Australia and SAN FRANCISCO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying [...]
Venus Concept Announces Intention to Voluntary Delist from Nasdaq and Deregister with SEC
21/01/2026
TORONTO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) announced today its voluntarily decision to delist its common stock from the NASDAQ Capital Market (“Nasdaq”) and [...]
BrainsWay Announces Draft Coverage Policy from Highmark® for Accelerated Deep TMS™
21/01/2026
New draft policy from Highmark Blue Cross Blue Shield extends to both adolescent and adult depression patients BURLINGTON, Mass. and JERUSALEM, Jan. 21, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY [...]
Restore Brain Announces Expansion of Neuromodulation Footprint with New St. Louis Office, Bringing Advanced TMS and SPRAVATO Treatments to the Region
21/01/2026
Dallas-based Restore Brain expands in Missouri, celebrating one year of advanced psychiatric care with innovative TMS and SPRAVATO® treatments Restore Brain Logo ST. LOUIS, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Restore [...]
American Heart Association and Centre for Neuro Skills Deepen Relationship to Advance Stroke and Brain Injury Care
21/01/2026
Multi-year Sponsorship Expands Across Texas and California with Educational Resources, Community Leadership and Patient Support BAKERSFIELD, Calif. and AUSTIN, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Centre for Neuro [...]
PetVivo Holdings, Inc. Announces Health Canada Acknowledgement of Spryng® as a Veterinary Medical Device
21/01/2026
MINNEAPOLIS, MN, Jan. 21, 2026 (GLOBE NEWSWIRE) -- PetVivo Animal Health, Inc., in cooperation with its parent PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) and affiliate PetVivo AI, Inc., an emerging biomedical [...]
LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel
21/01/2026
NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, [...]
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use
21/01/2026
California joins 23 other states eligible to receive free neffy ® (epinephrine nasal spray) at schools SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company [...]
DE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE
21/01/2026
Event Sponsored by LIXTE Biotechnology Holdings, Developer of Breakthrough Cancer Therapies Atlanta, GA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Inspired by the music, legacy, and lived experiences of De La Soul, the [...]
SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247
21/01/2026
The QIDP designation will ensure at least 10 years of market exclusivity for SCY-247 following approval Recent articles highlight the growing threat from a rapidly spreading, multi-drug resistant, Candida auris fungal [...]

Pages